Gut Microbe Bile Acid Isoallo-LCA Eases Acute Liver Transplant Rejection in Mice via NR4A1/FOXP3 Pathway

A secondary bile acid produced by gut bacteria has shown a striking ability to protect transplanted livers from acute rejection in mice, according to a new study published in Frontiers in Pharmacology. The molecule, isoallolithocholic acid (isoallo-LCA), is best known as a metabolite enriched in the intestines of centenarians, where it helps maintain immune homeostasis. Now, researchers at Army Medical University and Kunming Medical University report that daily injections of the compound significantly prolonged survival of liver graft recipients in a demanding mouse transplant model, while simultaneously reshaping the immune landscape inside the grafted organ.

The team set out to address a persistent problem in transplant medicine. Liver transplantation remains the most effective therapy for end-stage liver disease, but acute allograft rejection, driven largely by disordered CD4+ T cell responses, continues to threaten graft function and long-term recipient survival. Current immunosuppressants such as tacrolimus, cyclosporine, mycophenolate mofetil and sirolimus work by broadly suppressing T cell activation and proliferation. That blunt approach controls rejection but compromises systemic immune surveillance, raising the risk of opportunistic infections, malignancy and metabolic complications. The researchers hypothesized that a metabolite capable of fine-tuning immune cell differentiation rather than ablating it might offer a gentler path to tolerance.

To test the idea, the investigators established an orthotopic liver transplantation model with major histocompatibility complex mismatch: C57BL/6 mice donated livers, which were implanted into C3H recipient mice using the classic microsurgical cuff anastomosis technique. Recipients were randomly assigned to receive daily intraperitoneal injections of isoallo-LCA at 10 mg/kg body weight from postoperative day 0 through day 14, an equal volume of vehicle, or isoallo-LCA combined with an NR4A1 inhibitor. The compound used was verified at purity of at least 98 percent by high-performance liquid chromatography. Recipient survival was tracked continuously for Kaplan–Meier analysis, and graft tissue and blood were sampled on days 3, 7 and 14 after surgery.

The results were consistent across every endpoint measured. Kaplan–Meier analysis showed that isoallo-LCA significantly prolonged recipient survival compared with vehicle-treated animals, with a log-rank test yielding P = 0.012. Histopathological examination of graft tissue revealed severe inflammatory infiltration and parenchymal necrosis in control mice, lesions that were visibly relieved at all three time points in treated animals. Two blinded pathologists independently scored the grafts using the BANFF acute liver rejection grading criteria, and treated mice showed significantly milder rejection injury by day 14, with P < 0.01. Serum chemistry told the same story: alanine aminotransferase, aspartate aminotransferase and total bilirubin, all markers of hepatocyte damage, declined markedly after isoallo-LCA administration, with statistical significance ranging from P < 0.01 to P < 0.001.

Flow cytometry of graft-infiltrating lymphocytes revealed the cellular mechanism behind these improvements. In control mice, T-bet-positive CD4+ Th1 cells, the pro-inflammatory effectors that drive rejection, made up 14.57 percent of intrahepatic CD4+ T cells. After isoallo-LCA treatment, that proportion fell to 6.38 percent, a reduction of more than half. Meanwhile, FOXP3-positive regulatory T cells, the immunosuppressive population that restrains alloimmune attack, rose from 2.48 percent to 3.92 percent of the CD4+ compartment, with both shifts reaching P < 0.01. The authors note that although the absolute Treg increase of roughly 1.5 percentage points may appear modest, even small shifts in the Th1/Treg balance can carry substantial functional weight in the transplant microenvironment, and the concurrent collapse of the Th1 population produces a meaningful net tilt toward tolerance.

To identify the molecular pathway responsible, the team performed transcriptomic sequencing on graft tissue and used KEGG pathway enrichment analysis to map the resulting gene-expression changes. The NR4A1-associated signaling cascade emerged as the most significantly enriched pathway. NR4A1, also known as Nur77, is an orphan nuclear receptor that acts as a critical transcription factor in T cell development, activation and differentiation, and prior work has shown that it promotes FOXP3 expression and regulatory T cell differentiation by binding directly to the FOXP3 promoter. Western blot assays of liver allograft tissue confirmed that isoallo-LCA steadily elevated both NR4A1 and FOXP3 protein levels from day 3 through day 14 after transplantation.

In vitro experiments reinforced the link. Primary CD4+ T cells isolated from mouse spleens were cultured for 72 hours under three conditions: vehicle control, TGF-β1 alone, or TGF-β1 plus 10 micromolar isoallo-LCA. The cytokine-driven upregulation of NR4A1 and FOXP3 was further enhanced when isoallo-LCA was present, suggesting that the metabolite amplifies a natural tolerogenic differentiation program rather than imposing an artificial one.

The decisive evidence came from rescue experiments. When recipients received the NR4A1 inhibitor 1,10-phenanthroline alongside isoallo-LCA, the protective phenotype nearly vanished. The survival benefit was largely abrogated, with a log-rank P value of 0.003 for the comparison. The improved histopathology and reduced BANFF scores seen with isoallo-LCA alone were markedly reversed, and the declines in serum ALT, AST and total bilirubin were substantially recovered. Flow cytometry showed that the Treg frequency, which isoallo-LCA had raised from 2.30 percent to 3.87 percent, fell back to 2.62 percent when NR4A1 was blocked, a difference from the monotherapy group significant at P < 0.01. Western blots of graft-infiltrating lymphocytes confirmed that the inhibitor downregulated both NR4A1 and FOXP3, offsetting the metabolite’s upregulatory effect. Together, these data establish NR4A1 as an essential, not merely correlative, mediator of isoallo-LCA’s protective effects.

The study’s authors are careful to flag several caveats. Transcriptomic enrichment identifies NR4A1 pathway activation as a downstream consequence of treatment, but whether isoallo-LCA directly binds the NR4A1 protein remains unresolved and awaits direct binding studies. Intraperitoneal administration was chosen because recipients suffer severe intestinal dysfunction in the immediate post-transplant period, which would compromise oral absorption; whether this route recapitulates the physiological effects of gut-derived isoallo-LCA is an open question. The work also focused on CD4+ T cell subsets, leaving the compound’s effects on macrophages, dendritic cells and CD8+ T cells unexplored, and Treg differentiation is governed by parallel pathways including IL-2/STAT5, TGF-β/Smad and mTOR signaling, whose possible involvement has not been tested. All experiments were conducted in mice, and only acute rejection was examined, leaving chronic allograft injury and human translation as future questions.

Even with those limitations, the findings carry real translational weight. Gut microbiome composition varies widely between individuals, which could produce different endogenous isoallo-LCA levels and potentially different rejection risks, making microbiome profiling a plausible companion diagnostic in future trials. Because isoallo-LCA suppresses Th1 cells and promotes Tregs without generalized immune suppression, the authors position it as an adjunct agent that could reduce the dosage, and therefore the side-effect burden, of conventional immunosuppressants in the early post-transplant period. Unlike ursodeoxycholic acid, which primarily exerts cytoprotective effects, or lithocholic and deoxycholic acids, which act as FXR and TGR5 agonists, isoallo-LCA uniquely promotes NR4A1-mediated Treg differentiation, a distinct tolerogenic mechanism. The enrichment of isoallo-LCA-producing gut bacteria in centenarians hints at a natural tolerance-maintaining system that medicine may soon learn to harness, though the authors stress that clinical validation in human liver transplant recipients remains the necessary next step.

Subject of Research: Effects of the gut microbial bile acid isoallolithocholic acid on acute liver allograft rejection and Treg differentiation via NR4A1/FOXP3 in mice

Article Title: Isoallolithocholic acid attenuates acute liver allograft rejection by promoting Treg differentiation through the NR4A1/FOXP3 signaling axis

Article References: Luo, R., Huang, H., Zuo, Q., Zeng, Z., & Tang, T. (2026). Isoallolithocholic acid attenuates acute liver allograft rejection by promoting Treg differentiation through the NR4A1/FOXP3 signaling axis. Frontiers in Pharmacology, 17, 1953528. https://doi.org/10.3389/fphar.2026.1953528

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1953528

Keywords: isoallolithocholic acid, liver transplantation, acute allograft rejection, regulatory T cells, NR4A1, FOXP3, Th1 cells, gut microbiota, bile acid metabolites, immune tolerance, orthotopic liver transplantation, immunosuppression